An overview of carbohydrate-based carbonic anhydrase inhibitors

References

• Jensen EL, Clement R, Kosta A, et al. A new widespread subclass of carbonic anhydrase in marine phytoplankton. Isme J 2019;13:2094–106.
   PubMed Web of Science ®Google Scholar
• Del Prete S, Nocentini A, Supuran CT, et al. Bacterial ι-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem 2020; 35:1060–8.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.
   PubMed Web of Science ®Google Scholar
  (c) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• (a) Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2020;15:671–86.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin Drug Discov 2019;14:1175–97.
   PubMed Web of Science ®Google Scholar
• Chiche J, Ilc K, Laferrière J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009;69:358–68.
   PubMed Web of Science ®Google Scholar
• Annan DA, Maishi N, Soga T, et al. Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment. Cell Commun Signal 2019;17:169.
   PubMed Web of Science ®Google Scholar
• Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008–2013). Expert Opin Ther Pat 2013;23:737–49.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018;28:709–12.
   PubMed Web of Science ®Google Scholar
• Pinard MA, Mahon B, McKenna R. Probing the surface of human carbonic anhydrase for clues towards the design of isoform specific inhibitors. Biomed Res Int 2015;2015:453543.
   PubMed Web of Science ®Google Scholar
• Bozdag M, Ferraroni M, Nuti E, et al. Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: solution and X-ray crystallographic studies. Bioorg Med Chem 2014;22:334–40.
   PubMed Web of Science ®Google Scholar
• Kayser B, Dumont L, Lysakowski C, et al. Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta-analysis. High Alt Med Biol 2012;13:82–92.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT, Scozzafava A, Briganti F, et al. Carbonic anhydrase inhibitors - part 78(#). Synthesis of water-soluble sulfonamides incorporating beta-alanyl moieties, possessing long lasting-intraocular pressure lowering properties via the topical route. Eur J Med Chem 2000;35:309–21.
   PubMed Web of Science ®Google Scholar
  (b) Wang Z, Qin Y, Wang P, et al. Sulfonamides containing coumarin moieties selectively and potently inhibit carbonic anhydrases II and IX: design, synthesis, inhibitory activity and 3D-QSAR analysis. Eur J Med Chem 2013;66:1–11.
   PubMed Web of Science ®Google Scholar
• Bonardi A, Nocentini A, Bua S, et al. Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: improving ligand/isoform matching and selectivity of action. J Med Chem 2020;63:7422–44.
   PubMed Web of Science ®Google Scholar
• (a) Winum JY, Poulsen SA, Supuran CT. Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev 2009;29:419–35.
   PubMed Web of Science ®Google Scholar
  (b) Colinas PA. Novel glycomimetics: anomeric and N-Glycosyl Sulfonamides. Curr Org Chem 2012;16:1670–9.
   Web of Science ®Google Scholar
  (c) Winum JY, Colinas PA, Supuran CT. Glycosidic carbonic anhydrase IX inhibitors: a sweet approach against cancer. Bioorg Med Chem 2013;21:1419–26.
   PubMed Web of Science ®Google Scholar
• Latini G, Verrotti A, Manco R, et al. Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy. Mini Rev Med Chem 2008;8:10–23.
   PubMed Web of Science ®Google Scholar
• Maryanoff BE, Nortey SO, Gardocki JF, et al. Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds. J Med Chem 1987;30:880–7.
   PubMed Web of Science ®Google Scholar
• Maryanoff BE, McComsey DF, Costanzo MJ, et al. Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem 2005;48:1941–7.
   PubMed Web of Science ®Google Scholar
• Klinger AL, McComsey DF, Smith-Swintosky V, et al. Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem 2006;49:3496–500.
   PubMed Web of Science ®Google Scholar
• Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024–31.
   PubMed Web of Science ®Google Scholar
• Casini A, Antel J, Abbate F, et al. Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg Med Chem Lett 2003;13:841–5.
   PubMed Web of Science ®Google Scholar
• Lopez M, Paul B, Hofmann A, et al. S-glycosyl primary sulfonamides–a new structural class for selective inhibition of cancer-associated carbonic anhydrases. J Med Chem 2009;52:6421–32.
   PubMed Web of Science ®Google Scholar
• Lopez M, Drillaud N, Bornaghi F, et al. Synthesis of S-glycosyl primary sulfonamides. J Org Chem 2009;74:2811–6.
   PubMed Web of Science ®Google Scholar
• (a) Colinas PA, Tempera CA, Rodriguez OM, et al. Stereoselective synthesis of Novel N-β-glycosyl sulfonamides by sulfonamidoglycosylation of per-O-acetylated Sugars. Synthesis 2009;24:4143–8.
   Google Scholar
  (b) Rodriguez OM, Maresca A, Tempera CA, et al. N-β-glycosyl sulfamides are selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII. Bioorg Med Chem Lett 2011;21:4447–50.
   PubMed Web of Science ®Google Scholar
• Colinas PA, Bravo RD, Vullo D, et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I and II, and extracellular isoforms IV, IX, and XII with sulfamides incorporating sugar moieties. Bioorg Med Chem Lett 2007;17:5086–90.
   PubMed Web of Science ®Google Scholar
• Lopez M, Trajkovic J, Bornaghi LF, et al. Design, synthesis, and biological evaluation of novel carbohydrate-based sulfamates as carbonic anhydrase inhibitors. J Med Chem 2011;54:1481–9.
   PubMed Web of Science ®Google Scholar
• Lopez M, Vu H, Wang CK, et al. Promiscuity of carbonic anhydrase II. Unexpected ester hydrolysis of carbohydrate-based sulfamate inhibitors. J Am Chem Soc 2011;133:18452–62.
   PubMed Web of Science ®Google Scholar
• Winum JY, Thiry A, Cheikh KE, et al. Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranose-thioureido tails. Bioorg Med Chem Lett 2007;17:2685–91.
   PubMed Web of Science ®Google Scholar
• Moeker J, Mahon BP, Bornaghi LF, et al. Structural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates. J Med Chem 2014; 57:8635–45.
   PubMed Web of Science ®Google Scholar
• Mahon BP, Lomelino CL, Ladwig J, et al. Mapping selective inhibition of the cancer-related carbonic anhydrase IX using structure-activity relationships of glucosyl-based sulfamates. J Med Chem 2015; 58:6630–8.
   PubMed Web of Science ®Google Scholar
• Lopez M, Bornaghi LF, Innocenti A, et al. Sulfonamide linked neoglycoconjugates-a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem 2010; 53:2913–26.
   PubMed Web of Science ®Google Scholar
• Moeker J, Teruya K, Rossit S, et al. Design and synthesis of thiourea compounds that inhibit transmembrane anchored carbonic anhydrases. Bioorg Med Chem 2012;20:2392–404.
   PubMed Web of Science ®Google Scholar
• Hou Z, Li C, Liu Y, et al. Design, synthesis and biological evaluation of carbohydrate-based sulphonamide derivatives as topical antiglaucoma agents through selective inhibition of carbonic anhydrase II. J Enzyme Inhib Med Chem 2020;35:383–90.
   PubMed Web of Science ®Google Scholar
• Rostovtsev VV, Green LG, Fokin VV, et al. A stepwise huisgen cycloaddition process: copper(I)‐catalyzed regioselective “ligation” of azides and terminal alkynes. Angew Chem 2002;41:2596–9.
   Google Scholar
• (a) Himo B, Lovell T, Hilgraf R, et al. Copper(I)-catalyzed synthesis of azoles. DFT study predicts unprecedented reactivity and intermediates. J Am Chem Soc 2005;127:210–6.
   PubMed Web of Science ®Google Scholar
  (b) Worrell BT, Malik JA, Fokin VV. Direct evidence of a dinuclear copper intermediate in Cu(I)-catalyzed azide-alkyne cycloadditions. Science 2013;340:457–60.
   PubMed Web of Science ®Google Scholar
• Boren BC, Narayan S, Rasmussen LK, et al. Ruthenium-catalyzed azide-alkyne cycloaddition: scope and mechanism. J Am Chem Soc 2008;130:8923–30.
   PubMed Web of Science ®Google Scholar
• Jiang X, Hao X, Jing L, et al. Recent applications of click chemistry in drug discovery. Expert Opin Drug Discov 2019;14:779–89.
   PubMed Web of Science ®Google Scholar
• Nuti E, Cuffaro D, D'Andrea F, et al. Sugar-based arylsulfonamide carboxylates as selective and water-soluble matrix metalloproteinase-12 inhibitors. ChemMedChem 2016;11:1626–37.
   PubMed Web of Science ®Google Scholar
• D'Andrea F, Nuti E, Becherini S, et al. Design and synthesis of ionic liquid-based Matrix Metalloproteinase Inhibitors (MMPIs): a simple approach to increase hydrophilicity and to develop MMPI-coated gold nanoparticles. ChemMedChem 2019;14:686–98.
   PubMed Web of Science ®Google Scholar
• Tripathi RP, Dwivedi P, Sharma A, et al. Triazolyl glycoconjugates in medicinal chemistry. In: Witczak ZJ, Bielski R, eds. Click chemistry in glycoscience. Hoboken (NJ): John Wiley and Sons; 2013.
   Google Scholar
• Massarotti A, Aprile S, Mercalli V, et al. Are 1,4- and 1,5-disubstituted 1,2,3-triazoles good pharmacophoric groups? ChemMedChem 2014;9:2497–508.
   PubMed Web of Science ®Google Scholar
• Wilkinson BL, Bornaghi LF, Houston TA, et al. A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem 2006;49:6539–48.
   PubMed Web of Science ®Google Scholar
• Wilkinson BL, Bornaghi LF, Houston TA, et al. Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzene sulfonamides. Bioorg Med Chem Lett 2007;17:987–92.
   PubMed Web of Science ®Google Scholar
• Wilkinson BL, Innocenti A, Vullo D, et al. Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. J Med Chem 2008;51:1945–53.
   PubMed Web of Science ®Google Scholar
• Carroux CJ, Rankin GM, Moeker J, et al. A prodrug approach toward cancer-related carbonic anhydrase inhibition. J Med Chem 2013;56:9623–34.
   PubMed Web of Science ®Google Scholar
• Wilkinson BL, Bornaghi LF, Houston TA, et al. Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides. J Med Chem 2007;50:1651–7.
   PubMed Web of Science ®Google Scholar
• Singer M, Lopez M, Bornaghi LF, et al. Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties. Bioorg Med Chem Lett 2009;19:2273–6.
   PubMed Web of Science ®Google Scholar
• Morris JC, Chiche J, Grellier C, et al. Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem 2011;54:6905–18.
   PubMed Web of Science ®Google Scholar
• Murray AB, Lomelino CL, Supuran CT, et al. “Seriously sweet”: acesulfame K exhibits selective inhibition using alternative binding modes in carbonic anhydrase Isoforms. J Med Chem 2018;61:1176–−81.
   PubMed Web of Science ®Google Scholar
• Lomelino CL, Murray AB, Supuran CT, et al. Sweet binders: carbonic anhydrase IX in complex with sucralose. ACS Med Chem Lett 2018;9:657–61.
   PubMed Web of Science ®Google Scholar
• Mahon BP, Hendon AM, Driscoll JM, et al. Saccharin: a lead compound for structure-based drug design of carbonic anhydrase IX inhibitors. Bioorg Med Chem 2015;23:849–54.
   PubMed Web of Science ®Google Scholar
• Moeker J, Peat TS, Bornaghi LF, et al. Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes. J Med Chem 2014;57:3522–31.
   PubMed Web of Science ®Google Scholar
• Murray AB, Quadri M, Li H, et al. Synthesis of saccharin-glycoconjugates targeting carbonic anhydrase using a one-pot cyclization/deprotection strategy. Carbohydr Res 2019;476:65–70.
   PubMed Web of Science ®Google Scholar
• Salmon AJ, Williams ML, Maresca A, et al. Synthesis of glycoconjugate carbonic anhydrase inhibitors by ruthenium-catalysed azide-alkyne 1,3-dipolar cycloaddition. Bioorg Med Chem Lett 2011;21:6058–61.
   PubMed Web of Science ®Google Scholar
• Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem 2011;54:8271–7.
   PubMed Web of Science ®Google Scholar
• Maresca A, Scozzafava A, Supuran CT. 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorg Med Chem Lett 2010;20:7255–8.
   PubMed Web of Science ®Google Scholar
• Compain P. Glycomimetics: design, synthesis, and therapeutic applications. Molecules 2018;23:1658.
   Web of Science ®Google Scholar
• Asensio JL, Cañada FJ, Cheng X, et al. Conformational differences between O- and C-glycosides: the alpha-O-man-(1–>1)-beta-Gal/alpha-C-Man-(1–>1)-beta-Gal case–a decisive demonstration of the importance of the exo-anomeric effect on the conformation of glycosides. Chem Eur J 2000;6:1035–41.
   PubMed Web of Science ®Google Scholar
• Martínez HL, Riafrecha LE, Colinas PA. C-cinnamoyl glycosides: an emerging "Tail" for the development of selective carbonic anhydrase inhibitors. Curr Med Chem 2019;26:2601–8.
   PubMed Web of Science ®Google Scholar
• Riafrecha LE, Rodríguez OM, Vullo D, et al. Synthesis of C-cinnamoyl glycosides and their inhibitory activity against mammalian carbonic anhydrases. Bioorg Med Chem 2013;21:1489–94.
   PubMed Web of Science ®Google Scholar
• Buchieri MV, Riafrecha LE, Rodríguez OM, et al. Inhibition of the β-carbonic anhydrases from Mycobacterium tuberculosis with C-cinnamoyl glycosides: identification of the first inhibitor with anti-mycobacterial activity. Bioorg Med Chem Lett 2013;23:740–3.
   PubMed Web of Science ®Google Scholar
• Riafrecha LE, Vullo D, Ouahrani-Bettache S, et al. Inhibition of β-carbonic anhydrases from Brucella suis with C-cinnamoyl glycosides incorporating the phenol moiety. J Enzyme Inhib Med Chem 2015;30:1017–20.
   PubMed Web of Science ®Google Scholar
• Riafrecha LE, Rodríguez OM, Vullo D, et al. Attachment of carbohydrates to methoxyaryl moieties leads to highly selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII. Bioorg Med Chem 2014;22:5308–14.
   PubMed Web of Science ®Google Scholar
• Riafrecha LE, Vullo D, Supuran CT, et al. C-glycosides incorporating the 6-methoxy-2-naphthyl moiety are selective inhibitors of fungal and bacterial carbonic anhydrases. J Enzyme Inhib Med Chem 2015;30:857–61.
   PubMed Web of Science ®Google Scholar
• Zaro MJ, Bortolotti A, Riafrecha LE, et al. Anti-tubercular and antioxidant activities of C-glycosyl carbonic anhydrase inhibitors: towards the development of novel chemotherapeutic agents against Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2016;31:1726–30.
   PubMed Web of Science ®Google Scholar
• Riafrecha LE, Bua S, Supuran CT, et al. Improving the carbonic anhydrase inhibition profile of the sulfamoylphenyl pharmacophore by attachment of carbohydrate moieties. Bioorg Chem 2018;76:61–6.
   PubMed Web of Science ®Google Scholar
• Tanpure RP, Ren B, Peat TS, et al. Carbonic anhydrase inhibitors with dual-tail moieties to match the hydrophobic and hydrophilic halves of the carbonic anhydrase active site. J Med Chem 2015;58:1494–501.
   PubMed Web of Science ®Google Scholar
• Hou Z, Lin B, Bao Y, et al. Dual-tail approach to discovery of novel carbonic anhydrase IX inhibitors by simultaneously matching the hydrophobic and hydrophilic halves of the active site. Eur J Med Chem 2017;132:1–10.
   PubMed Web of Science ®Google Scholar
• Maresca A, Akyuz G, Osman SM, et al. Inhibition of mammalian carbonic anhydrase isoforms I-XIV with a series of phenolic acid esters. Bioorg Med Chem 2015;23:7181–8.
   PubMed Web of Science ®Google Scholar